Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1988 1
1989 1
1998 2
1999 2
2001 2
2002 4
2003 2
2004 8
2005 4
2006 4
2007 7
2008 13
2009 15
2010 16
2011 24
2012 17
2013 31
2014 21
2015 27
2016 18
2017 28
2018 31
2019 44
2020 47
2021 55
2022 61
2023 49
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Yu EY, et al. Among authors: liang sy. Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12. Lancet Oncol. 2021. PMID: 33991512 Clinical Trial.
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Rosenberg JE, et al. Among authors: liang sy. J Clin Oncol. 2019 Oct 10;37(29):2592-2600. doi: 10.1200/JCO.19.01140. Epub 2019 Jul 29. J Clin Oncol. 2019. PMID: 31356140 Free PMC article. Clinical Trial.
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.
Ju WT, Xia RH, Zhu DW, Dou SJ, Zhu GP, Dong MJ, Wang LZ, Sun Q, Zhao TC, Zhou ZH, Liang SY, Huang YY, Tang Y, Wu SC, Xia J, Chen SQ, Bai YZ, Li J, Zhu Q, Zhong LP. Ju WT, et al. Among authors: liang sy. Nat Commun. 2022 Sep 14;13(1):5378. doi: 10.1038/s41467-022-33080-8. Nat Commun. 2022. PMID: 36104359 Free PMC article. Clinical Trial.
Tau Toxicity in Neurodegeneration.
Liang SY, Wang ZT, Tan L, Yu JT. Liang SY, et al. Mol Neurobiol. 2022 Jun;59(6):3617-3634. doi: 10.1007/s12035-022-02809-3. Epub 2022 Mar 31. Mol Neurobiol. 2022. PMID: 35359226 Review.
Infections in Older Adults.
Scott MM, Liang SY. Scott MM, et al. Among authors: liang sy. Emerg Med Clin North Am. 2021 May;39(2):379-394. doi: 10.1016/j.emc.2021.01.004. Epub 2021 Mar 23. Emerg Med Clin North Am. 2021. PMID: 33863466 Review.
478 results